Europium-Doped Cerium Oxide Nanoparticles for Microglial Amyloid Beta Clearance and Homeostasis
Alzheimer's disease (AD) is the most common neurodegenerative disorder. Pathologically, the disease is characterized by the deposition of amyloid beta (Aβ) plaques and the presence of neurofibrillary tangles. These drive microglia neuroinflammation and consequent neurodegeneration. While the means to affect Aβ plaque accumulation pharmacologically was achieved, how it affects disease outcomes remains uncertain. Cerium oxide (CeO2) reduces Aβ plaques, oxidative stress, inflammation, and AD signs and symptoms. In particular, CeO2 nanoparticles (CeO2NPs) induce free-radical-scavenging and cell protective intracellular signaling. This can ameliorate the pathobiology of an AD-affected brain. To investigate whether CeO2NPs affect microglia neurotoxic responses, a novel formulation of europium-doped CeO2NPs (EuCeO2NPs) was synthesized. We then tested EuCeO2NPs for its ability to generate cellular immune homeostasis in AD models. EuCeO2NPs attenuated microglia BV2 inflammatory activities after Aβ1-42 exposure by increasing the cells' phagocytic and Aβ degradation activities. These were associated with increases in the expression of the CD36 scavenger receptor. EuCeO2NPs facilitated Aβ endolysosomal trafficking and abrogated microglial inflammatory responses. We posit that EuCeO2NPs may be developed as an AD immunomodulator.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
ACS chemical neuroscience - 13(2022), 8 vom: 20. Apr., Seite 1232-1244 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Machhi, Jatin [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 21.04.2022 Date Revised 12.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1021/acschemneuro.1c00847 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338427708 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338427708 | ||
| 003 | DE-627 | ||
| 005 | 20231226000643.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1021/acschemneuro.1c00847 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1128.xml |
| 035 | |a (DE-627)NLM338427708 | ||
| 035 | |a (NLM)35312284 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Machhi, Jatin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Europium-Doped Cerium Oxide Nanoparticles for Microglial Amyloid Beta Clearance and Homeostasis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.04.2022 | ||
| 500 | |a Date Revised 12.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Alzheimer's disease (AD) is the most common neurodegenerative disorder. Pathologically, the disease is characterized by the deposition of amyloid beta (Aβ) plaques and the presence of neurofibrillary tangles. These drive microglia neuroinflammation and consequent neurodegeneration. While the means to affect Aβ plaque accumulation pharmacologically was achieved, how it affects disease outcomes remains uncertain. Cerium oxide (CeO2) reduces Aβ plaques, oxidative stress, inflammation, and AD signs and symptoms. In particular, CeO2 nanoparticles (CeO2NPs) induce free-radical-scavenging and cell protective intracellular signaling. This can ameliorate the pathobiology of an AD-affected brain. To investigate whether CeO2NPs affect microglia neurotoxic responses, a novel formulation of europium-doped CeO2NPs (EuCeO2NPs) was synthesized. We then tested EuCeO2NPs for its ability to generate cellular immune homeostasis in AD models. EuCeO2NPs attenuated microglia BV2 inflammatory activities after Aβ1-42 exposure by increasing the cells' phagocytic and Aβ degradation activities. These were associated with increases in the expression of the CD36 scavenger receptor. EuCeO2NPs facilitated Aβ endolysosomal trafficking and abrogated microglial inflammatory responses. We posit that EuCeO2NPs may be developed as an AD immunomodulator | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Alzheimer’s disease (AD) | |
| 650 | 4 | |a BV2 cells and immune modulation | |
| 650 | 4 | |a amyloid beta (Aβ) | |
| 650 | 4 | |a cerium oxide | |
| 650 | 4 | |a europium-doped cerium oxide nanoparticles (EuCeO2NPs) | |
| 650 | 4 | |a microglia | |
| 650 | 7 | |a Amyloid beta-Peptides |2 NLM | |
| 650 | 7 | |a Cerium |2 NLM | |
| 650 | 7 | |a 30K4522N6T |2 NLM | |
| 650 | 7 | |a Europium |2 NLM | |
| 650 | 7 | |a 444W947O8O |2 NLM | |
| 650 | 7 | |a ceric oxide |2 NLM | |
| 650 | 7 | |a 619G5K328Y |2 NLM | |
| 700 | 1 | |a Yeapuri, Pravin |e verfasserin |4 aut | |
| 700 | 1 | |a Markovic, Milica |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Milankumar |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Wenhui |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Yaman |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, Jacob D |e verfasserin |4 aut | |
| 700 | 1 | |a Hasan, Mahmudul |e verfasserin |4 aut | |
| 700 | 1 | |a Abdelmoaty, Mai Mohamed |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, You |e verfasserin |4 aut | |
| 700 | 1 | |a Xiong, Huangui |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xinglong |e verfasserin |4 aut | |
| 700 | 1 | |a Mosley, R Lee |e verfasserin |4 aut | |
| 700 | 1 | |a Gendelman, Howard E |e verfasserin |4 aut | |
| 700 | 1 | |a Kevadiya, Bhavesh D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ACS chemical neuroscience |d 2010 |g 13(2022), 8 vom: 20. Apr., Seite 1232-1244 |w (DE-627)NLM19578832X |x 1948-7193 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |g number:8 |g day:20 |g month:04 |g pages:1232-1244 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1021/acschemneuro.1c00847 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 |e 8 |b 20 |c 04 |h 1232-1244 | ||